What does the evidence show about Pinealon (EDR tripeptide / Glu-Asp-Arg)'s effects?

Read Off Label rates the evidence for Pinealon (EDR tripeptide / Glu-Asp-Arg) as Preclinical and the benefit magnitude as variable, producing an overall grade of C+ (5.3/10). Same evidence-quality caveats as Epithalon and Thymalin: nearly all data originates from Khavinson's St.

What safety findings are reported for Pinealon (EDR tripeptide / Glu-Asp-Arg)?

Pinealon (EDR tripeptide / Glu-Asp-Arg) has a low risk profile in the database. Low (case-series reports; no Western RCT safety data) Legal status: Research chemical (not FDA-approved).

What doses or routes are reported for Pinealon (EDR tripeptide / Glu-Asp-Arg)?

100 mcg-10 mg SC daily for 10-20 day courses, cycled 1-2x/year (biohacker protocols vary widely) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.

Rankings / Longevity — Peptides

Pinealon (EDR tripeptide / Glu-Asp-Arg)

Longevity · Pineal peptide bioregulator

Tier C+

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

peptidenootropicneuroprotectiveepigeneticresearch-only

5.3 / 10

Tier C+

Ev 2 Bn 5 Sf 9

Bottom line

Read Off Label grades Pinealon (EDR tripeptide / Glu-Asp-Arg) as C+ (5.3/10) based on preclinical evidence, variable benefit magnitude, and a low-risk safety profile.

Same evidence-quality caveats as Epithalon and Thymalin: nearly all data originates from Khavinson's St.

Studied, labeled, or reported-use context: 100 mcg-10 mg SC daily for 10-20 day courses, cycled 1-2x/year (biohacker protocols vary widely) — Research chemical; not individualized guidance.

What the evidence says

Same evidence-quality caveats as Epithalon and Thymalin: nearly all data originates from Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and collaborators — limited independent Western peer review. The Khavinson framework proposes that 2-4 amino acid "cytogen" peptides act as tissue-specific gene expression modulators via electrostatic binding to chromatin. Best mechanistic paper: Khavinson 2021 "EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease" (Int J Mol Sci PMC7795577). Best preclinical: Khavinson 2021 Pharmaceuticals 14:515 — KED and EDR peptides prevented dendritic spine loss in 5xFAD mice. Only direct human study identified: Kryzhanovskaya 2014 cognitive enhancement trial in 60 healthy adults aged 45-65 — small; not replicated in the West. Distinct from melatonin (sometimes co-marketed as a "pineal" compound but mechanism is unrelated). The evidence has the same limitations as the broader Russian peptide bioregulator family: plausible mechanisms and a decades-old Russian clinical tradition but no Western RCTs. Most online-channel material is research-chemical grade without documented GMP oversight.

Mechanism

Synthetic Glu-Asp-Arg (EDR) tripeptide from Khavinson's St. Petersburg Institute of Bioregulation and Gerontology; pineal-extract-derived (a tripeptide sibling of Epithalon's tetrapeptide); proposed to penetrate cell nuclei and bind promoter regions of neuroprotective genes (antioxidant enzymes; anti-apoptotic factors; neurotrophic regulators); preclinical evidence of dendritic-spine preservation in 5xFAD Alzheimer mouse model

Studied, labeled, or reported dose & route

100 mcg-10 mg SC daily for 10-20 day courses, cycled 1-2x/year (biohacker protocols vary widely)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Pinealon (EDR tripeptide / Glu-Asp-Arg)'s effects?: Read Off Label rates the evidence for Pinealon (EDR tripeptide / Glu-Asp-Arg) as Preclinical and the benefit magnitude as variable, producing an overall grade of C+ (5.3/10). Same evidence-quality caveats as Epithalon and Thymalin: nearly all data originates from Khavinson's St.
What safety findings are reported for Pinealon (EDR tripeptide / Glu-Asp-Arg)?: Pinealon (EDR tripeptide / Glu-Asp-Arg) has a low risk profile in the database. Low (case-series reports; no Western RCT safety data) Legal status: Research chemical (not FDA-approved).
What doses or routes are reported for Pinealon (EDR tripeptide / Glu-Asp-Arg)?: 100 mcg-10 mg SC daily for 10-20 day courses, cycled 1-2x/year (biohacker protocols vary widely) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Pinealon (EDR tripeptide / Glu-Asp-Arg) work?: Synthetic Glu-Asp-Arg (EDR) tripeptide from Khavinson's St. Petersburg Institute of Bioregulation and Gerontology; pineal-extract-derived (a tripeptide sibling of Epithalon's tetrapeptide); proposed to penetrate cell nuclei and bind promoter regions of neuroprotective genes (antioxidant enzymes; anti-apoptotic factors; neurotrophic regulators); preclinical evidence of dendritic-spine preservation in 5xFAD Alzheimer mouse model

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.